Delcath Systems (NASDAQ:DCTH) Stock Price Expected to Rise, BTIG Research Analyst Says

Delcath Systems (NASDAQ:DCTH) had its target price hoisted by analysts at BTIG Research from $17.00 to $21.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s target price indicates a potential upside of 38.98% from the company’s current price.

Other equities analysts also recently issued research reports about the company. Weiss Ratings raised Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Zacks Research upgraded shares of Delcath Systems from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Delcath Systems has a consensus rating of “Moderate Buy” and an average target price of $23.17.

Delcath Systems Stock Performance

Shares of DCTH stock opened at $15.11 on Thursday. The firm’s 50 day moving average price is $12.35 and its two-hundred day moving average price is $10.87. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $16.38. The stock has a market cap of $521.60 million, a PE ratio of 1,512.51 and a beta of 0.52.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.16. The company had revenue of $29.13 million during the quarter, compared to analysts’ expectations of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.47%. As a group, sell-side analysts predict that Delcath Systems will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of Delcath Systems

A number of large investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new position in shares of Delcath Systems during the 2nd quarter valued at $26,000. Russell Investments Group Ltd. bought a new position in shares of Delcath Systems in the third quarter valued at approximately $29,000. Tower Research Capital LLC TRC bought a new stake in Delcath Systems during the second quarter worth $40,000. Legal & General Group Plc purchased a new stake in Delcath Systems in the 2nd quarter valued at $46,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Delcath Systems in the second quarter valued at about $151,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems News Summary

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Quarterly earnings beat expectations: Delcath reported second-quarter earnings of $0.07 per share, versus the consensus estimate for a $0.09 loss, while revenue of $29.13 million exceeded expectations of $26.25 million. Earnings matched the year-ago quarter and represent a significant improvement relative to analyst forecasts. MarketBeat earnings report Zacks earnings coverage
• Positive Sentiment: Revenue outlook is above consensus: The company issued fiscal 2026 revenue guidance of $104 million to $108 million, ahead of the approximately $103.3 million analyst consensus. The outlook reinforces expectations for continued commercial growth. Benzinga guidance coverage
• Positive Sentiment: Analyst price target increased: BTIG Research raised its DCTH price target from $17 to $21 and maintained a Buy rating, signaling greater confidence in the company’s growth prospects and implying substantial potential upside from recent trading levels. Benzinga analyst coverage
• Positive Sentiment: Momentum and investor attention increased: Coverage highlighted DCTH’s best trading session in nearly 15 months and a new 52-week high, while volume was more than twice its recent average. These technical signals likely amplified the reaction to the earnings beat. MSN 52-week-high coverage
• Neutral Sentiment: Investors are assessing the earnings-call outlook: Management’s second-quarter conference call focused on operating performance and the updated fiscal 2026 outlook. The guidance is encouraging, although the stock’s valuation remains demanding, with a very high reported price-to-earnings ratio. Seeking Alpha earnings call transcript

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.